Roche’s new AAN 2020 data Event
Agenda:
Welcome
Risdiplam: FIREFISH part 2 efficacy and safety in infants with type 1 SMA
Risdiplam: Update on clinical development program
OCREVUS: Long-term data on key markers of disability progression in MS Shorter infusion (ENSEMBLE PLUS) data and regulatory update
Q&A
Karl Mahler, Head of Investor Relations and Roche Group Planning
Prof. Laurent Servais, MDUK Oxford Neuromuscular Center, Department of Paediatrics, University of Oxford, UK
Paulo Fontoura, M.D. Ph.D., Global Head Neuroscience and Rare Diseases Clinical Development

Please register to access the replay*

*Privacy notice

Live webinar

Roche has hosted a live audio webcast and conference call on Tuesday, 28 April 2020.

Investors
Past IR Events
View more Events

Downloads

Related links